Navigation Links
The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke

LOVENOX(R) should be used with extreme caution. Thrombocytopenia of any degree should be monitored closely. If the platelet count falls below 100,000/mm3, LOVENOX(R) should be discontinued. Cases of heparin-induced thrombocytopenia have been observed in clinical practice. (See WARNINGS).

The use of LOVENOX(R) has not been adequately studied for thromboprophylaxis in pregnant women with mechanical prosthetic heart valves. (See WARNINGS).

LOVENOX(R) is contraindicated in patients with hypersensitivity to enoxaparin sodium, heparin, or pork products, and in patients with active major bleeding.

Please see accompanying full prescribing information including boxed WARNING.

Please visit http://www.lovenox.com for complete prescribing information, including boxed WARNING, and additional important information.

About sanofi-aventis

Sanofi-aventis is one of the world's leading pharmaceutical companies. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris and in New York .

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventi
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
3. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
4. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
5. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
8. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
9. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
10. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
11. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
Post Your Comments:
(Date:7/21/2014)... AVIV, Israel , July 21, 2014 ... a clinical-stage biopharmaceutical company focused on the development and ... of liver diseases and cholesterol gallstones, announced today that ... Friday, July 25, 2014 to discuss results for the ... update on current developments with respect to its clinical ...
(Date:7/21/2014)... , July 21, 2014  Zacks.com announces the list ... Zacks Equity Research analysts discuss the latest news and events ... the blog include the Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH - ... Report ), Eli Lilly and Company (NYSE: LLY - ... ) and InterMune, Inc. (Nasdaq: ITMN - Free Report ...
(Date:7/21/2014)... DIEGO , July 21, 2014 Sorrento ... late-stage clinical oncology company developing new treatments for cancer ... received non-dilutive funding for the preclinical development of a ... Myc. The Myc protein has also ... and protein synthesis. It is involved as a dominant ...
Breaking Medicine Technology:Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014 2The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 2The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 3The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 4The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 5The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 6The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 7Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 2Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 3Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 4
...  Communication channels are becoming increasingly plentiful in today,s ... drive efficient performance, increase profitability and raise consumer ... companies need to identify which external and internal ... best use them. Best Practices, ...
... 2012  Par Pharmaceutical Companies, Inc. (NYSE: ... the acquisition of privately-held Edict Pharmaceuticals Private Limited, ... Par paid $20.5 million at closing and $4.4 ... Edict is a Chennai, India-based developer and manufacturer ...
Cached Medicine Technology:Effective Communication Options to Increase Organizational Effectiveness 2Par Pharmaceutical Completes Acquisition of Edict Pharmaceuticals 2
(Date:7/22/2014)... 2014 An Ideal Location , Narconon ... the naturally tranquil and very beautiful Arrowhead State Park, ... ideal for both a rehabilitative setting, as well as ... display of fireworks. Launched over the waters of ... swimming in the lake, or from the nearby campgrounds ...
(Date:7/22/2014)... UT (PRWEB) July 22, 2014 MonaVie ... joins its Scientific Advisory Board (SAB). The addition of ... expertise to support current product development plans and necessary ... stranger to MonaVie, Macdonald has been with the company ... was influential in helping formulate MonaVie’s RVL ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Joining Conquer Paralysis ... paralysis in the next decade is Paralympic silver medalist and ... accident, French became a quadriplegic from a spinal cord injury ... help find a cure for paralysis. , “People define cure ... others, it’s something else. We have the image in our ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Ocean ... center located in Pompano Beach, Florida, has ... the Joint Commission, an independent not-for-profit organization that ... Accreditation signifies that the quality programs offered at ... standards for safety and performance. Ocean Breeze, which ...
(Date:7/22/2014)... JumpSoft, Inc., a next generation software ... the application level, today released its “App-Hugger” report ... , Based on in-depth, one-on-one interviews ... insights, context and depth regarding the challenges facing ... uptime. London, Ink, a B2B marketing consulting firm, ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Holds Annual Firework Event 2Health News:Narconon Arrowhead Holds Annual Firework Event 3Health News:MonaVie Adds Nutritionist Mark Macdonald to Its Scientific Advisory Board 2Health News:MonaVie Adds Nutritionist Mark Macdonald to Its Scientific Advisory Board 3Health News:Paralympian Jen French Announced as Conquer Paralysis Now’s First Champion 2Health News:Florida Drug and Alcohol Addiction Treatment Center Receives Joint Commission Seal of Approval 2Health News:Florida Drug and Alcohol Addiction Treatment Center Receives Joint Commission Seal of Approval 3Health News:JumpSoft Releases Report on Shift from Infrastructure-Centric to Application-Centric IT Management 2Health News:JumpSoft Releases Report on Shift from Infrastructure-Centric to Application-Centric IT Management 3
... The same type of change that has come ... to U.S. Preventive Medicine, the leader in prevention.(Logo: ... faces and policies to our capital, the time is ... approach to health care," said Christopher Fey, Chairman and ...
... FJC, a foundation of philanthropic donor-advised funds and the ... the "Cure Myeloma Project", an ongoing research initiative at ... in Los Angeles, CALOS ANGELES, Jan. 26 IMBCR,s ... find a cure for multiple myeloma, a blood cancer ...
... form strong connections to particular product brands,when their ... to a new study in the, Journal of ... of Wisconsin-Madison and Korea,University), James E. Burroughs (University ... levels of materialism and insecurity,in consumers and discovered ...
... discount on the initial franchise fee and a place ... Jan. 26 Despite the challenging economic climate in ... experienced retail employees their jobs - the supplement and ... to grow at a rate of 4%-6% each year, ...
... incentives to foster healthy choices.LYNDHURST, N.J., Jan. 26 ... solutions to the healthcare industry, announced today that ... a new "points-based" health incentive program with IncentOne,s ... employers ways to motivate their employees toward improved ...
... in their twenties and thirties are more likely to develop ... study of more than 800 men published in the January ... research team also found that frequent sexual activity in a ... levels of activity in a man,s fifties could offer protection ...
Cached Medicine News:Health News:U.S. Preventive Medicine Recommends Changing CDC Name to Centers for Disease Prevention and Control 2Health News:1.2 Million Dollars Recently Awarded to Institute for Myeloma and Bone Cancer Research 2Health News:Security blankets: Materialism and death anxiety lead to brand loyalty 2Health News:Lost Your Job in Retail? Why Not Operate Your Own Business in 2009! Invest in You. Become an Entrepreneur! 2Health News:Lost Your Job in Retail? Why Not Operate Your Own Business in 2009! Invest in You. Become an Entrepreneur! 3Health News:IncentOne Provides Incentive Solution to CIGNA 2Health News:Frequent sex and masturbation in 20s and 30s linked to higher prostate cancer risk 2Health News:Frequent sex and masturbation in 20s and 30s linked to higher prostate cancer risk 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: